Development of effective vaccines against pandemic influenza.
about
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particleHeterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cellsLive, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferretsVaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypesInfluenza: the once and future pandemicImmunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificityPredominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparednessChoice and Design of Adjuvants for Parenteral and Mucosal VaccinesTwo Distinct Conformations of a Rinderpest Virus Epitope Presented by Bovine Major Histocompatibility Complex Class I N*01801: a Host Strategy To Present Featured PeptidesMutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibilityLarge-scale sequence analysis of hemagglutinin of influenza A virus identifies conserved regions suitable for targeting an anti-viral responseEfficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules.Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccineModulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis.Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutininToward a method for tracking virus evolutionary trajectory applied to the pandemic H1N1 2009 influenza virus.Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targetsActivation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.Passive broad-spectrum influenza immunoprophylaxisSynthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen.Efficient strategy for constructing duck enteritis virus-based live attenuated vaccine against homologous and heterologous H5N1 avian influenza virus and duck enteritis virus infection.A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.Induction of long-term protective immune responses by influenza H5N1 virus-like particles.Current status and progress of prepandemic and pandemic influenza vaccine development.Vaccines for an influenza pandemic: scientific and political challenges.Microneedle-based vaccinesMicroneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice.Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccineRegulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.CD4+/CD8+ T lymphocytes imbalance in children with severe 2009 pandemic influenza A (H1N1) pneumonia.Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunityCross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles.The prospects and challenges of universal vaccines for influenzaAntigenic characterization of recombinant hemagglutinin proteins derived from different avian influenza virus subtypes.Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responsesContributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunityComparative Safety and Efficacy Profile of a Novel Oil in Water Vaccine Adjuvant Comprising Vitamins A and E and a Catechin in Protective Anti-Influenza Immunity.
P2860
Q21562299-A32A0F30-6690-4B80-8C3D-37F1EE577397Q21562507-FAE8107F-A177-42C4-A172-20A124F3EC44Q21563426-2C6653E0-074E-42C0-A59C-B132CB6A47E7Q24614628-94DAA220-5B09-4693-A9D5-AB916F8832D0Q24630177-C6D7F7A1-D480-4276-8517-7EAEED85F5ADQ24646829-EF872AAE-3D36-4D42-8E58-4BB6326B0F02Q24647318-0C8F8479-7FDE-41DE-B2FB-5063C77DE8B4Q26783488-730D0C8F-B11A-4EB6-A895-B94478F594CFQ27667354-EE4B8722-CDFB-43D3-8D2A-2AE578B9CC18Q28385604-1B482EDC-0CBD-4019-A394-F2A80650D216Q28748869-FD971289-2ED4-4715-978E-A99B046B299BQ30204348-4B792B73-018F-4B0F-8EBB-43642EE36349Q30229190-82C5360B-175A-4A09-8E12-AAC428579AD4Q30359683-52C65803-CE3E-4E6A-AFFA-AA7D47917ECAQ30361736-0D7D27C0-CE1B-4931-9D0D-803E863F7534Q30365146-DB87F13F-D1B7-4361-8A9F-9F5F416FB169Q30366017-F17EA378-711C-4BC3-B124-BA8C5BA1890BQ30367140-A00D91C5-09E8-468C-9CE4-D0C22A9C5A32Q30367936-E71B0ED1-7F39-4296-BF34-B37EE797A90EQ30373251-8AA90D97-9432-4948-AEB2-D4A2630F9168Q30373912-D7EA9A5B-5097-4508-AD3E-A666BDD62C3FQ30374887-8CB7A650-502A-4DFB-A4D2-9042478F6F86Q30375255-830A08FB-6B3A-4A27-BDF0-95D9FE363A1CQ30375975-75A5D445-5A3B-48DE-9912-64DE508CF7CFQ30376971-5451B811-371E-4069-9A11-7BBAD0DEF2C9Q30380910-9E78D494-3E08-45A8-849C-F5EF1D5AFA68Q30391402-CF1B6028-ABEC-4E00-9CBE-86E2868F423EQ30398228-936F19BF-8A59-4CE8-8B65-21D17DFB1F29Q30400146-4522EED1-1FDA-4723-B21C-5AF1C480B69FQ30400347-98FA57AC-5E1B-4A87-B1A8-C029307CFFC9Q30405842-714A1172-7C24-4D9E-9FB5-9461F2ACB5B6Q30412222-61CC846C-45EE-461A-B890-12C9D4AF9EC9Q30420603-5165936A-96E2-4804-9283-280A1752EB8EQ30421682-E7A6B5BD-5494-45B0-A518-804D7460D8F2Q30430152-2DFE1FBD-F97C-457C-B3D6-D4D1C40C64DAQ30430703-15238BB6-0CF2-43DE-BE98-D13761AE12ADQ33530075-A6B898C3-77CA-4479-BE20-33E75C73B927Q33614507-73289923-9A45-4D57-8A3D-4F0FAC05647CQ33648987-4A5C5662-B668-49F2-A1B1-B12216E1D4A9Q33749602-53B30CD9-F364-4CEC-9CE2-578E2B3DFE15
P2860
Development of effective vaccines against pandemic influenza.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Development of effective vaccines against pandemic influenza.
@ast
Development of effective vaccines against pandemic influenza.
@en
type
label
Development of effective vaccines against pandemic influenza.
@ast
Development of effective vaccines against pandemic influenza.
@en
prefLabel
Development of effective vaccines against pandemic influenza.
@ast
Development of effective vaccines against pandemic influenza.
@en
P1433
P1476
Development of effective vaccines against pandemic influenza.
@en
P2093
Brian R Murphy
P356
10.1016/J.IMMUNI.2005.12.005
P407
P577
2006-01-01T00:00:00Z